Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
复制标题
对中国公立医院药品采购决策框架的影响：确定五种二肽基肽酶4（DPP-4）抑制剂的价值
DOI：
10.1186/s12913-021-06827-0
复制
发表时间：
2021-08-12
影响因子：
2.8
通讯作者：
Tian L
中科院分区：
文献类型：
--
作者：
Bao Y;Gao B;Meng M;Ge B;Yang Y;Ding C;Shi B;Tian L
背景中国公立医院的药品采购是由医院药事管理委员会(PMC)决定的，这是复杂的、主观的，需要有效的方法来确保所考虑因素的透明度和一致性。这项研究旨在使用证据和价值：对决策的影响(EVIDEM)框架来评估这些医院的药物。在这项研究中，我们评价了抗糖尿病药物DPP-4抑制剂，这些药物通过抑制二肽基肽酶4(DPP-4)抑制剂的激活来发挥作用。方法遵循EVIDEM方法(EVIDEM-10)，我们召集了一个评估小组，要求每个人通过给每个标准分配权重来表达他们的观点。对5种DPP-4抑制剂的每个标准的信息进行系统的文献检索。然后评估组对五种DPP-4抑制剂中的每一项标准进行评分。通过多准则决策分析(MCDA)得到5种DPP-4抑制剂的估计值。结果通过赋权，最重要的指标是证据质量(4.01±0.52)，而比较成本后果-非医疗费用是最不重要的指标(2.87±1.03)。标准包括疾病严重程度、受影响人口的大小、相对有效性、治疗/预防益处的类型和干预成本，所有这些都被赋予相同的权重3.58。MCDA后，各DPP-4抑制剂的总价值大小顺序为：Sitagliptin(0.45)、Linagliptin(0.44)、Vildagliptin(0.43)、Alogliptin(0.42)和saxagliptin(0.40)。结论根据EVIDEM框架和MCDA，我们发现5种DPP-4抑制剂的总价值相似。将EVIDEM框架和MCDA应用于我国公立医院的药品采购是可行的。
BackgroundMedicine purchasing in Chinese public hospitals is decided by the hospital Pharmacy Management Committee (PMC), that is complex, subjective and requires efficient approaches to ensure transparency and consistency for the factors being considered. This study aimed to use the Evidence and Value: Impact on Decision Making (EVIDEM) framework to assess medicine in these hospitals. In this study anti-diabetic drugs DPP-4 inhibitors, which work by inhibiting the activation of the Dipeptidyl Peptidase 4 (DPP-4) inhibitors, were appraised.MethodsFollowing EVIDEM methodology (EVIDEM-10th), we convened an appraisal group and asked each individual to express their perspectives by assigning weights to each criterion. A systematic literature search for information of each criterion of five DPP-4 inhibitors was completed. Then the appraisal group scored for each criterion of the five DPP-4 inhibitors. The estimated value of the five DPP-4 inhibitors was obtained by Multi-Criteria Decision Analysis (MCDA) which combined individual weighting of each criterion with individual scoring for each intervention in each criterion.ResultsBy assigning weights, the most important criterion was the quality of evidence (4.01±0.52), and that the comparative cost consequences-non-medical cost was the least important criterion (2.87±1.03). Criteria included disease severity, size of the affected population, comparative effectiveness, type of therapeutic/preventive benefit and cost of intervention, all of which were assigned the same weight of 3.58. After MCDA, the overall value orders for each DPP-4 inhibitor included Sitagliptin (0.45), Linagliptin (0.44), Vildagliptin (0.43), Alogliptin (0.42) and Saxagliptin (0.40).ConclusionsBased on EVIDEM framework and MCDA, we found that overall value of five DPP-4 inhibitors was similar. It is feasible to use the EVIDEM framework and MCDA in purchasing medicine for Chinese public hospitals.
登录
查看更多内容
DOI：
10.1186/s12962-018-0116-9
发表时间：
2018
期刊：
Cost effectiveness and resource allocation : C/E
影响因子：
--
作者：
Goetghebeur MM;Cellier MS
通讯作者：
Cellier MS
影响因子：
3.6
作者：
DOLAN, JG
通讯作者：
DOLAN, JG
影响因子：
2.8
作者：
Tony M;Wagner M;Khoury H;Rindress D;Papastavros T;Oh P;Goetghebeur MM
通讯作者：
Goetghebeur MM
影响因子：
4.5
作者：
Thokala, Praveen;Devlin, Nancy;Ijzerman, Maarten
通讯作者：
Ijzerman, Maarten
影响因子：
3.8
作者：
Craddy, Paul;Palin, Hannah-Jayne;Johnson, K. Ian
通讯作者：
Johnson, K. Ian